Not Applicable.
The present invention relates generally to a mattress for a hospital bed, and more specifically to a therapeutic mattress having an air composite patient support surface and a rigid perimeter.
Mattresses, including therapeutic overlays which assist in preventing bed sores, for hospital beds are well known in the art. While such mattresses and overlays according to the prior art provide a number of advantageous features, they nevertheless have certain limitations. The present invention seeks to overcome certain of these limitations and other drawbacks of the prior art, and to provide new features not heretofore available. A full discussion of the features and advantages of the present invention is deferred to the following detailed description, which proceeds with reference to the accompanying drawings.
The present invention generally provides a therapeutic mattress having a base layer, a patient support layer above the base layer, and an encasing over the base layer and the patient support layer. This therapeutic mattress is provided to assist in preventing bed sores and decreasing existing bedsores on patients.
According to one embodiment, the base layer comprises a base member, a foam end member and a plurality of foam side panels connected to the base member. The base member may be comprised of foam, gel, fluid or some other pressure compensating media. Further, the base member may be comprised of one or more inflatable and/or non-inflatable components. Generally, the side panels extend from a head end of the base member to a foot end of the base member of the mattress to create a cavity or well to support the patient support layer.
According to another embodiment, the patient support layer is provided in the well of the base layer. The patient support layer has a plurality of sections or zones. In a preferred embodiment one of the plurality of sections is made of an inflatable component, and another of the plurality of sections is made of a non-inflatable component. The non-inflatable component may also comprise a plurality of individual air cells fluidly interconnected. In one embodiment, the patient support layer comprises alternating foam portions and air cell portions. Further, in another embodiment the patient support layer comprises a first foam layer adjacent a head end of the mattress, a first air mattress portion adjacent the foot end of the mattress, a second air mattress portion adjacent the first foam layer, and a second foam layer adjacent the first air mattress portion.
According to yet another embodiment, the encasing comprises a removable cover having a cavity. Further, in a preferred embodiment the encasing comprises a lower encasing connected with a zipper to an upper encasing. In one embodiment, the upper encasing comprises a urethane coated spandex to allow the top cover to be breathable but substantially impervious to water.
Other features and advantages of the invention will be apparent from the following specification taken in conjunction with the following drawings.
To understand the present invention, it will now be described by way of example, with reference to the accompanying drawings in which:
While this invention is susceptible of embodiments in many different forms, there is shown in the drawings and will herein be described in detail preferred embodiments of the invention with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the broad aspect of the invention to the embodiments illustrated.
Referring now to the Figures, and specifically
As shown in the Figures, the therapeutic mattress 10 has a head end 18 and a foot end 20 opposing the head end 18, a first side 22 and a second side 24 opposing the first side 24. The term “head end” is used to denote the end of any referred to object that is positioned to lie nearest the head end 18 of the mattress 10, and the term “foot end” is used to denote the end of any referred to object that is positioned to lie nearest the foot end 20 of the mattress 10. Generally, the therapeutic mattress 10 provides components for the various sections of the base layer 14 and patient support layer 16 of the mattress 10 that have varying levels of pressure relief and deflection as measured in units of either indentation load deflection (ILD) or pressure.
In one embodiment, the base layer 14 of the mattress 10 comprises a bottom member 28 and a perimetral frame. The perimetral frame provides support and shape to the mattress 10 and generally contains the patient support layer 16 within a defined boundary. In one embodiment, the perimetral frame comprises first and second opposing transverse side panels or members 30, 32, and a first end member 34. It is understood that in alternate embodiments, as discussed herein, a second end member opposing the first end member 34 may be provided to provide a perimetral frame that traverses about the entire perimeter of the mattress 10 interior of the encasing 12.
The bottom member 38 is preferably made of a high density, high resilient, low compression open cell urethane foam that is fire retardant and is set for medical bedding. In one embodiment the bottom member 28 is approximately 3″ thick and has an ILD value of generally greater than 30, and preferably 40. The bottom member 28 in the embodiment shown extends generally from the head end 18 to the foot end 20 of the mattress 10, and generally from the first side 22 to the second side 24 of the mattress 10. In alternate embodiments the bottom member 38 may be much thinner, allowing for a thicker patient support layer 16. Additionally, it is understood that instead of being comprised of foam, one or more sections or portions of the bottom member 28 may be comprised of a gel, fluid or other pressure compensating media, generally referred to as a non-inflatable component. Further, the bottom member 28 may be comprised of one or more inflatable and/or non-inflatable components. The bottom member 28 may also be comprised of a foam having a plurality of independently projecting foam cells.
In various embodiments the bottom member 28 is a substantially flat and unitary member, as shown in
As shown in
In the embodiments shown, the side members 30, 32 extend approximately from the head end 18 of the mattress 10 to the foot end 20 of the mattress 10. The side members 30, 32 are connected to the side edges 36, 38 of the bottom member 28, preferably at the contact surfaces at each side 22, 24, respectively, thereof. As shown in
Similarly, the end member 34 is also preferably made of a high density, high resilient, low compression open cell urethane foam that is fire retardant and is set for medical bedding. In one embodiment, like the side members 30, 32, the end member 34 is approximately 2″ thick by 6.25″ high, and it has an ILD value which is greater than the ILD value of the bottom member 28. Additionally, in a preferred embodiment the ILD value of the end member 34 is substantially similar to the ILD value of the side members 30, 32, and in a most preferred embodiment the ILD value of the end member 34 is generally greater than 40, and preferably 65.
As shown in
As explained above, a second end member may be provided at the head end 18 of the mattress 10. This second end member would typically be secured to the head end 18 of the bottom member 28, and the head end 18 of the first and second side members 30, 32, similar to the securement of the first end member 34 to the foot end 20 of the bottom member 28.
Because the side members 30, 32 and the end member 34 of the base are approximately 6.25″ high and the bottom member 28 is approximately 3″ high, a cavity or well 46 that is approximately 3.25″ deep is defined between the bottom member 28 and the opposing side members 30, 32 and end member 34. Alternate embodiments employing different thicknesses of the bottom member 28 and different thicknesses of the components making up the perimetral frame will have different depths of the well or cavity 46. This cavity 46 is preferably utilized to house the patient support layer 16 as explained and shown herein.
Referring to
In preferred embodiments, various zones or sections of the patient support layer 16 are made of a non-inflatable component 58, and different zones or sections of the patient support layer 16 are made of an inflatable or air mattress component 60. For example, in the embodiment of
While different non-inflatable materials may be utilized without departing from the scope of the present invention, in one embodiment the first foam component 62 utilized in the head zone 50 adjacent the head end 18 of the mattress 10 is a urethane memory-type foam that is fire retardant and is set for medical bedding. Further, in a preferred embodiment, the foam component 62 for the head zone 50 has a density of between 2.0 and 6.0 lbs, and preferably at least 2.5 lbs but generally not greater than 5.0 lbs. Alternately, the foam component 62 for the head zone 50 may be referred to as having an ILD value of between 15 and 40 ILD. Additionally, the foam component 62 for the head zone 50 has a first side 70 adjacent the first side member 30, and a second side 72 adjacent the second side member 32. Moreover, in one embodiment the foam component 62 in the head zone 50 is approximately 3.25″ thick to fill the cavity or well 46 of the base layer 14, which in one embodiment is approximately 3.25″ deep as explained above. Preferably, the ILD value of the foam component 62 for the head zone 50 is less than the ILD value of both the bottom member 28 and the side members 30, 32 of the base member 14. In one embodiment the foam component 62 for the head zone 50 is fixed, typically with an adhesive as explained above, to the base layer 14.
Similarly, in one embodiment the second foam component 66 utilized in the knee zone 56 is a urethane memory-type foam that is fire retardant and is set for medical bedding. Further, in a preferred embodiment, the foam component 66 for the knee zone 56 has a density of between 2.0 and 6.0 lbs, and preferably at least 2.5 lbs but not greater than 5.0 lbs. Alternately, the foam component 66 for the knee zone 56 may be referred to as having an ILD value of between 15 and 40 ILD. As shown in
In one embodiment, a first inflatable air mattress component 68 is utilized in the foot zone 52, and a second inflatable air mattress component 64 is utilized in the seat zone 54. Alternately, additionally inflatable components 60 may also be utilized in the head zone 50 and knee zone 56. In a preferred embodiment, as shown in the figures, the inflatable components generally comprise a plurality of low-pressure, soft, fluidly interconnected but independently movable, air-filled cells 78 which are able to redistribute air pressure between each of the cells 78 in the inflatable component to conform to the contours of a patient's body with minimal tissue deformation to provide a friction and shear relief surface. Such inflatable components are typically non-powered, meaning they are in a closed system. The air cells 78 are generally arranged in an array of rows and columns which are fluidly connected across a flexible base 80 on the inflatable components 60. In one embodiment, the air cells 78 have a substantially rectangular body that is approximately 3.5″ high, with a top wall that has a generally pyramidal or conical shape thereto. Further, the air cells 78 have a generally square cross-sectional shape. Generally, like the foam mattress portions 58 of the patient support member 16, the air mattress components 60 are provided in the cavity or well 46 of the base layer 14, and extend from the first side member 30 to the second side member 32 of the base layer 14. In one embodiment, as disclosed in
The air cells 78 can be adjusted to the patient's body shape and size. In a preferred embodiment, the inflatable components 60 are provided in a closed system, meaning they are non-powered and require no external power source once they are inflated to the appropriate pressure. Thus, after the inflatable components 60 are inflated, they are maintained at that pressure, however, should any leakage or seepage occur they may be re-inflated to the desired pressure. In a preferred embodiment, the inflatable components 60 are made of a durable neoprene rubber that is flame-resistant and can be easily cleaned. Each of the inflatable components 60 of the different zones can be removed and replaced, if necessary. Further, the inflatable components 60 can be connected to adjacent members, including foam members, typically by snapping together, connecting with Velcro, or by some other acceptable means.
In the embodiment shown in
Referring now to
Several alternative embodiments and examples have been described and illustrated herein. A person of ordinary skill in the art would appreciate the features of the individual embodiments, and the possible combinations and variations of the components. A person of ordinary skill in the art would further appreciate that any of the embodiments could be provided in any combination with the other embodiments disclosed herein. Additionally, the terms “first,” “second,” “third,” and “fourth” as used herein are intended for illustrative purposes only and do not limit the embodiments in any way. Further, the term “plurality” as used herein indicates any number greater than one, either disjunctively or conjunctively, as necessary, up to an infinite number. Additionally, the term “having” as used herein in both the disclosure and claims, is utilized in an open-ended manner.
It will be understood that the invention may be embodied in other specific forms without departing from the spirit or central characteristics thereof. The present examples and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and the invention is not to be limited to the details given herein. Accordingly, while the specific embodiments have been illustrated and described, numerous modifications come to mind without significantly departing from the spirit of the invention and the scope of protection is only limited by the scope of the accompanying Claims.
This application is a continuation of application Ser. No. 11/650,737, filed on Jan. 8, 2007 and issued as U.S. Pat. No. 7,509,698, which is a continuation of application Ser. No. 11/349,683, filed on Feb. 8, 2006 and issued as U.S. Pat. No. 7,536,739, which is a continuation-in-part of U.S. Provisional Patent Application Ser. No. 60/707,074, filed on Aug. 10, 2005. The disclosures of all of the above-mentioned patent and patent applications are expressly incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3394415 | Parker | Jul 1968 | A |
3605145 | Graebe | Sep 1971 | A |
3701173 | Whitney | Oct 1972 | A |
3872525 | Lea et al. | Mar 1975 | A |
4042988 | Holliday | Aug 1977 | A |
4224706 | Young et al. | Sep 1980 | A |
4391009 | Schild et al. | Jul 1983 | A |
4449261 | Magnusson | May 1984 | A |
4686725 | Mitchell | Aug 1987 | A |
4706313 | Murphy | Nov 1987 | A |
4897890 | Walker | Feb 1990 | A |
4901387 | Luke | Feb 1990 | A |
4947500 | Seiler | Aug 1990 | A |
4949414 | Thomas et al. | Aug 1990 | A |
4977629 | Jones | Dec 1990 | A |
4986738 | Kawasaki et al. | Jan 1991 | A |
5025519 | Spann et al. | Jun 1991 | A |
5031261 | Fenner, Sr. | Jul 1991 | A |
5039158 | Maier | Aug 1991 | A |
5070560 | Wilkinson | Dec 1991 | A |
5107558 | Lück | Apr 1992 | A |
5109560 | Uetake | May 1992 | A |
5117521 | Foster et al. | Jun 1992 | A |
5121513 | Thomas et al. | Jun 1992 | A |
5129115 | Higgins et al. | Jul 1992 | A |
5163196 | Graebe et al. | Nov 1992 | A |
5179742 | Oberle | Jan 1993 | A |
5182826 | Thomas et al. | Feb 1993 | A |
5233974 | Senoue et al. | Aug 1993 | A |
5243721 | Teasdale | Sep 1993 | A |
5249319 | Higgs | Oct 1993 | A |
5252278 | Spann et al. | Oct 1993 | A |
5259079 | Visser et al. | Nov 1993 | A |
5325551 | Tappel et al. | Jul 1994 | A |
5335651 | Foster et al. | Aug 1994 | A |
5337845 | Foster et al. | Aug 1994 | A |
5370111 | Reeder et al. | Dec 1994 | A |
D355322 | Ackley et al. | Feb 1995 | S |
5398354 | Balonick et al. | Mar 1995 | A |
5412821 | Wilkinson | May 1995 | A |
5425148 | Ashcraft et al. | Jun 1995 | A |
5454142 | Neely et al. | Oct 1995 | A |
5457831 | Foster et al. | Oct 1995 | A |
5461741 | Graebe | Oct 1995 | A |
5479666 | Foster et al. | Jan 1996 | A |
5483709 | Foster et al. | Jan 1996 | A |
5497766 | Foster et al. | Mar 1996 | A |
5513406 | Foster et al. | May 1996 | A |
5551107 | Graebe | Sep 1996 | A |
5562091 | Foster et al. | Oct 1996 | A |
5568660 | Raburn et al. | Oct 1996 | A |
5577279 | Foster et al. | Nov 1996 | A |
5580504 | Spann et al. | Dec 1996 | A |
5586346 | Stacy et al. | Dec 1996 | A |
5596781 | Graebe | Jan 1997 | A |
5606754 | Hand et al. | Mar 1997 | A |
5611096 | Bartlett et al. | Mar 1997 | A |
5613255 | Bish et al. | Mar 1997 | A |
5630238 | Weismiller et al. | May 1997 | A |
5634224 | Gates | Jun 1997 | A |
5642546 | Shoenhair | Jul 1997 | A |
5649331 | Wilkinson et al. | Jul 1997 | A |
5652985 | Wilkinson et al. | Aug 1997 | A |
5666681 | Meyer et al. | Sep 1997 | A |
5672849 | Foster et al. | Sep 1997 | A |
5680661 | Foster et al. | Oct 1997 | A |
5689845 | Sobieralski | Nov 1997 | A |
5708997 | Foster et al. | Jan 1998 | A |
5715548 | Weismiller et al. | Feb 1998 | A |
5731062 | Kim et al. | Mar 1998 | A |
5745937 | Weismiller et al. | May 1998 | A |
5781949 | Weismiller et al. | Jul 1998 | A |
5845352 | Matsler et al. | Dec 1998 | A |
5933888 | Foster et al. | Aug 1999 | A |
5963998 | Carew et al. | Oct 1999 | A |
5983429 | Stacy et al. | Nov 1999 | A |
5987668 | Ackley | Nov 1999 | A |
6036271 | Wilkinson et al. | Mar 2000 | A |
6047424 | Osborne et al. | Apr 2000 | A |
6098222 | Hand et al. | Aug 2000 | A |
6112345 | Foster et al. | Sep 2000 | A |
6119291 | Osborne et al. | Sep 2000 | A |
6151739 | Meyer et al. | Nov 2000 | A |
6163903 | Weismiller et al. | Dec 2000 | A |
6212714 | Allen et al. | Apr 2001 | B1 |
6223369 | Maier et al. | May 2001 | B1 |
6256821 | Boyd | Jul 2001 | B1 |
6256822 | Weston et al. | Jul 2001 | B1 |
6269504 | Romano et al. | Aug 2001 | B1 |
6269505 | Wilkinson | Aug 2001 | B1 |
6286166 | Henley et al. | Sep 2001 | B1 |
6324709 | Ikeda et al. | Dec 2001 | B1 |
6351863 | Meyer et al. | Mar 2002 | B1 |
6353950 | Bartlett et al. | Mar 2002 | B1 |
6374436 | Foster et al. | Apr 2002 | B1 |
6415814 | Hand et al. | Jul 2002 | B1 |
6446283 | Heimbrock et al. | Sep 2002 | B1 |
6481033 | Fogel | Nov 2002 | B2 |
6496993 | Allen et al. | Dec 2002 | B2 |
6499167 | Ellis et al. | Dec 2002 | B1 |
6536056 | Vrzalik et al. | Mar 2003 | B1 |
6560793 | Walker | May 2003 | B2 |
6584628 | Kummer et al. | Jul 2003 | B1 |
6601253 | Tarquinio | Aug 2003 | B1 |
6611979 | Welling et al. | Sep 2003 | B2 |
6623080 | Clapper | Sep 2003 | B2 |
6640361 | Heimbrock et al. | Nov 2003 | B2 |
6662393 | Boyd | Dec 2003 | B2 |
6684427 | Allen et al. | Feb 2004 | B2 |
6687936 | Graebe et al. | Feb 2004 | B2 |
6694548 | Foster et al. | Feb 2004 | B2 |
6701556 | Romano et al. | Mar 2004 | B2 |
6725474 | Foster et al. | Apr 2004 | B2 |
6745996 | Guthrie | Jun 2004 | B1 |
6751815 | Heimbrock et al. | Jun 2004 | B2 |
6782574 | Totton et al. | Aug 2004 | B2 |
6820640 | Hand et al. | Nov 2004 | B2 |
6826795 | Wilkinson | Dec 2004 | B2 |
6874185 | Phillips et al. | Apr 2005 | B1 |
6880189 | Welling et al. | Apr 2005 | B2 |
6892405 | Dimitriu et al. | May 2005 | B1 |
6901617 | Sprouse, II et al. | Jun 2005 | B2 |
6904631 | Vrzalik et al. | Jun 2005 | B2 |
6922863 | Giori et al. | Aug 2005 | B2 |
6928681 | Stacy | Aug 2005 | B1 |
6952852 | Reeder et al. | Oct 2005 | B2 |
6976281 | Schunk et al. | Dec 2005 | B2 |
6990700 | Chung | Jan 2006 | B2 |
7017208 | Weismiller et al. | Mar 2006 | B2 |
7039972 | Chaffee | May 2006 | B2 |
7044460 | Bolton | May 2006 | B2 |
7076818 | Kummer et al. | Jul 2006 | B2 |
7082635 | Barman et al. | Aug 2006 | B2 |
7086107 | Ellis et al. | Aug 2006 | B2 |
7114207 | Wang | Oct 2006 | B2 |
7120950 | Garrigues | Oct 2006 | B2 |
7120955 | Wang | Oct 2006 | B2 |
7127762 | Lau | Oct 2006 | B1 |
7188379 | James et al. | Mar 2007 | B2 |
7191482 | Romano et al. | Mar 2007 | B2 |
7191483 | Hochschild | Mar 2007 | B2 |
7225488 | Wu | Jun 2007 | B2 |
7229134 | Ito | Jun 2007 | B2 |
7296313 | Hense | Nov 2007 | B2 |
7296314 | Wyatt et al. | Nov 2007 | B2 |
7313837 | Wang | Jan 2008 | B2 |
7346945 | Phillips et al. | Mar 2008 | B2 |
7509698 | Poulos | Mar 2009 | B2 |
7536739 | Poulos | May 2009 | B2 |
20050028289 | Hakamium | Feb 2005 | A1 |
20050034764 | Hand et al. | Feb 2005 | A1 |
20050166330 | Williams | Aug 2005 | A1 |
20060031995 | Barkhouse | Feb 2006 | A1 |
Number | Date | Country |
---|---|---|
8610640 | Jun 1986 | DE |
8714843 | Feb 1998 | DE |
0465810 | Jan 1992 | EP |
1086681 | Mar 2001 | EP |
WO 9804170 | Feb 1998 | WO |
Number | Date | Country | |
---|---|---|---|
20090183313 A1 | Jul 2009 | US |
Number | Date | Country | |
---|---|---|---|
60707074 | Aug 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11650737 | Jan 2007 | US |
Child | 12383326 | US | |
Parent | 11349683 | Feb 2006 | US |
Child | 11650737 | US |